Despite a dip in revenue and an increased net loss, IRIDEX Corp (IRIX) remains committed to strategic initiatives and market leadership in ophthalmic treatments.
Iridex (IRIX) delivered earnings and revenue surprises of -75% and 1.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?